Aduro Biotech Stock News

The combined company will have US$200-million in cash and three drug candidates to treat rare, chronic kidney treatments affecting hundreds of thousands of people globally

Chinook Therapeutics and Aduro Biotech, each pursuing different approaches to the same rare disease, are now converging on a path to combine their

The Dow and S&P are seeing modest gains, while the tech-rich Nasdaq slipped into the red midday

Looking into the current session, Aduro Biotech Inc. (NASDAQ: ADRO) is trading at $2.83, after a 15.88% drop. Over the past month, the stock fell by 5.33%, but over the past year, it actually increase

Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL)

– Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy –.

As of late, it has definitely been a great time to be an investor in Aduro Biotech.

Aduro Biotech (ADRO) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Is (ADRO) Outperforming Other Medical Stocks This Year?

Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL)

Aduro Biotech (ADRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Aduro Biotech, Inc. (NASDAQ:ADRO) shareholders will have a reason to smile today, with the analysts making substantial...

As you might know, Aduro Biotech, Inc. (NASDAQ:ADRO) just kicked off its latest quarterly results with some very...

Aduro Biotech (ADRO) delivered earnings and revenue surprises of 18.18% and 58.34%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

BERKELEY, Calif., May 04, 2020 -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of.